BioSpace News Archive

Jack Nathan Medical Corp., a provider of primary care medical clinics located in Walmart® Supercentres under the Jack Nathan Health® brand, announced the acquisition of its 8172 sq.

Sonnet BioTherapeutics Holdings, Inc., a biopharmaceutical company developing innovative targeted biologic drugs, announced the appointment of Richard Kenney, M.D. as Chief Medical Officer and Manuel Dafonseca, as Head of Clinical Operations, effective March 22, 2021.

Ontada TM , McKesson ’s oncology technology and insights business, announced today that respected real-world data expert Susan Shiff has joined as President. In this role, Shiff will continue to build on Ontada’s momentum in delivering real-world insights to transform the fight against cancer.

Cybin Inc., a biotechnology company focused on progressing psychedelic therapeutics, announced that it has signed a drug development agreement with Catalent, Inc. the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products.

XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors approved a dividend of $0.71875 per share to holders of XOMA’s Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP).

Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company, today announced that Rand Sutherland, MD, MPH, has been appointed President effective March 22, 2021,

Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that it has entered into a definitive license agreement under which the company, through a subsidiary, has acquired additional global rights to a non-steroidal anti-inflammatory technology that forms the basis of the companys EB01 and EB02 drug candidates.

Calyx, the imaging and eClinical solutions and services provider most relied on for solving complex data challenges in clinical research, today announced an expansion to its Executive Leadership Team, appointing Dr. Stephen M. Bravo as its Chief Medical Officer (CMO).

Amolyt Pharma today presented positive data from the first cohorts of the single ascending dose portion of its Phase 1 clinical trial in healthy volunteers evaluating the company’s lead clinical candidate, AZP-3601, for the treatment of hypoparathyroidism. The data demonstrated a significant, sustained increase in blood calcium levels for at least 24 hours following a single administration of AZP-3601.

Decibel Therapeutics (Nasdaq: DBTX) (“Decibel”), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that it has been added to the Russell 2000® Index, as part of the index’s quarterly initial public offering (“IPO”) additions.